Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label multicenter study of bezuclastinib in advanced systemic mastocytosis
MOH_2023-10-20_012995Phase 2Not yet recruiting
- Sponsor
- Cogent Biosciences
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bezuclastinib in systemic mastocytosis (SM), Aggressive Systemic Mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN) and 1 more (7 arms), sponsored by Cogent Biosciences. Primary endpoints: Dose optimization, Dose confirmation and 1 more. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
bezuclastinib
03
Conditions
systemic mastocytosis (SM)Aggressive Systemic Mastocytosis (ASM)systemic mastocytosis with associated hematological neoplasm (SM-AHN)mast cell leukemia (MCL)
Beyond the preview
Go deeper on MOH_2023-10-20_012995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-20_012995.